Karen A Cadoo,Diana L Mandelker,Semanti Mukherjee,Carolyn Stewart,Deborah DeLair,Vignesh Ravichandran,Preethi Srinivasan,Daire Hurley,Yelena Kemel,Angela G Arnold,Margaret Sheehan,Nisha Pradhan,Vijai Joseph,Dennis S Chi,Ginger J Gardner,Elizabeth L Jewell,Mario M Leitao Jr,Kara Long Roche,Jennifer J Mueller,Yukio Sonoda,Oliver Zivanovic,Michael Walsh,Maria I Carlo,Michael F Berger,David Hyman,Liying Zhang,Mark E Robson,Kenneth Offit,Carol Aghajanian,Nadeem R Abu Rustum,Zsofia Stadler

Abstract:Purpose: Mutations in DNA mismatch repair (MMR) genes and PTEN, diagnostic of Lynch and Cowden syndromes, respectively, represent the only established inherited predisposition genes in endometrial cancer to date. The prevalence of other cancer predisposition genes remains unclear. We sought the prevalence of pathogenic germline variants in unselected patients with endometrial cancer attending for surgical consultation. Patients and methods: Patients were prospectively consented (4/2016-5/2017) to an IRB-approved protocol of tumor-normal sequencing via a custom next-generation sequencing panel (MSK-IMPACT) with return of germline results for >75 cancer predisposition genes. Tumors were assessed for microsatellite instability (MSI). Per institutional standards, all tumors underwent Lynch syndrome screening via IHC for MMR proteins. Results: Of 156 patients who consented to germline genetic testing, 118 (76%) had stage I disease. Tumors were endometrioid in 104 (67%), of which 60 (58%) were grade 1. Twenty-four pathogenic germline variants were identified in 22 patients (14%)-7 (4.5%) with highly penetrant cancer syndromes and 15 (9.6%) with variants in moderate-, low-penetrance, or recessive genes. Of these, 5 (21%) were in Lynch syndrome genes (2 MSH6, 2 PMS2, and 1 MLH1). All 5 tumors had concordant IHC staining; 2 (40%) were definitively MSI-high by next-generation sequencing. One patient had a known BRCA1 mutation; 1 had SMARCA4 deletion. The remaining 17 variants (71%) were incremental findings in moderate- and low-penetrance variants or genes associated with recessive disease. Conclusion: In unselected patients with predominantly low-risk, early-stage endometrial cancer, germline multi-gene panel testing identifies cancer predisposition gene variants in 14%. This finding may have implications for future cancer screening and risk-reduction recommendations. Universal IHC screening for Lynch syndrome successfully identifies the majority (71%) of high-penetrance germline mutations.

Endometrial Cancer in a Family With RAD51D Gene Mutation

Candidate Locus Analysis of the TERT – CLPTM1L Cancer Risk Region on Chromosome 5p15 Identifies Multiple Independent Variants Associated with Endometrial Cancer Risk

Germline genetic variants in a case of familial cancer: RAD51D and four other co-segregated variants

Homologous Recombination Deficiency Among Patients With RAD51C/D Breast or Ovarian Cancer

Mutação RAD51D e o câncer de mama: relato de caso e achados de literatura

Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.

Germline DNA Damage Repair Gene Alterations in Patients with Metachronous Breast and Colorectal Cancer

Long-term Survival of an Ovarian Cancer Patient Harboring a RAD51C Missense Mutation.

Incidence of endometrial cancer in BRCA mutation carriers

Germline copy number variants and endometrial cancer risk

Fine-mapping of the HNF1B Multicancer Locus Identifies Candidate Variants That Mediate Endometrial Cancer Risk.

Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients with Ovarian Cancer

Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer

RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer.

Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer

New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability

RAD50 Germline Mutations Are Associated with Poor Survival in BRCA1/2-negative Breast Cancer Patients.

Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis.

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC

Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes (ATM, BRIP1, RAD51C, RAD51D, and PALB2)